These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27845153)

  • 1. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: Role of prior daptomycin exposure.
    DiPippo AJ; Tverdek FP; Tarrand JJ; Munita JM; Tran TT; Arias CA; Shelburne SA; Aitken SL
    J Infect; 2017 Mar; 74(3):243-247. PubMed ID: 27845153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Continuous and Sequential Therapy among Veterans Receiving Daptomycin or Linezolid for Vancomycin-Resistant Enterococcus faecium Bacteremia.
    Britt NS; Potter EM; Patel N; Steed ME
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
    Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.
    Kirkizlar TA; Akalin H; Kirkizlar O; Ozkalemkas F; Ozkocaman V; Kazak E; Ozakin C; Bulbul EN; Ozboz ES; Ali R
    Leuk Res; 2020 Dec; 99():106463. PubMed ID: 33130331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy.
    Lewis JS; Owens A; Cadena J; Sabol K; Patterson JE; Jorgensen JH
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1664-5. PubMed ID: 15793168
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients.
    Britt NS; Potter EM; Patel N; Steed ME
    Clin Infect Dis; 2015 Sep; 61(6):871-8. PubMed ID: 26063715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing outcomes of adult oncology patients treated with linezolid versus daptomycin for bacteremia due to vancomycin-resistant Enterococcus.
    Patel K; Kabir R; Ahmad S; Allen SL
    J Oncol Pharm Pract; 2016 Apr; 22(2):212-8. PubMed ID: 25326010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of high-dose daptomycin for bacteremia caused by daptomycin-susceptible Enterococcus faecium harboring LiaSR substitutions.
    Munita JM; Mishra NN; Alvarez D; Tran TT; Diaz L; Panesso D; Reyes J; Murray BE; Adachi JA; Bayer AS; Arias CA
    Clin Infect Dis; 2014 Nov; 59(9):1277-80. PubMed ID: 25107294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.
    Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chen YC; Chang SC
    Clin Infect Dis; 2017 Apr; 64(8):1026-1034. PubMed ID: 28329222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of adjusting for enterococcus species when assessing the burden of vancomycin resistance: a cohort study including over 1000 cases of enterococcal bloodstream infections.
    Kramer TS; Remschmidt C; Werner S; Behnke M; Schwab F; Werner G; Gastmeier P; Leistner R
    Antimicrob Resist Infect Control; 2018; 7():133. PubMed ID: 30459945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study.
    Echeverria-Esnal D; Sorli L; Prim N; Conde-Estévez D; Mateu-De Antonio J; Martin-Ontiyuelo C; Horcajada JP; Grau S
    Int J Antimicrob Agents; 2019 Nov; 54(5):572-578. PubMed ID: 31476435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of vancomycin-resistant Enterococcus bloodstream infections in southern Taiwan.
    Chou CH; Lee NY; Lee HC; Chang CM; Lee CC; Ko WC
    J Microbiol Immunol Infect; 2012 Jun; 45(3):221-7. PubMed ID: 22578639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF; Friedrich LV; Yankelev S; Lamp KC
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of Patients With Vancomycin-Resistant Enterococcus faecium Bacteremia Treated With Conventional or High Doses of Daptomycin or Linezolid Is Associated With the Rate of Bacterial Clearance.
    Chuang YC; Lin HY; Chen PY; Lin CY; Chen YC; Wang JT; Chang SC
    Crit Care Med; 2018 Oct; 46(10):1634-1642. PubMed ID: 29957707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.
    Chuang YC; Chen PY; Lin CY; Chen YC; Wang JT; Chang SC
    Sci Rep; 2018 Jan; 8(1):1632. PubMed ID: 29374204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.
    Kinnear CL; Patel TS; Young CL; Marshall V; Newton DW; Read AF; Woods RJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Low Susceptibility to Daptomycin in Enterococcus faecium Bacteremia.
    Namikawa H; Yamada K; Shibata W; Fujimoto H; Takizawa E; Niki M; Nakaie K; Nakamura Y; Oinuma KI; Niki M; Takemoto Y; Kaneko Y; Shuto T; Kakeya H
    Tohoku J Exp Med; 2017 Nov; 243(3):211-218. PubMed ID: 29187672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.
    Egli A; Schmid H; Kuenzli E; Widmer AF; Battegay M; Plagge H; Frei R; Achermann R; Weisser M
    Clin Microbiol Infect; 2017 Feb; 23(2):118.e1-118.e7. PubMed ID: 27746397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin versus linezolid for the treatment of vancomycin-resistant enterococcal bacteraemia: implications of daptomycin dose.
    Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chang SC
    Clin Microbiol Infect; 2016 Oct; 22(10):890.e1-890.e7. PubMed ID: 27475738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.
    King ST; Usery JB; Holloway K; Koeth L; Cleveland KO; Gelfand MS
    J Antimicrob Chemother; 2011 Nov; 66(11):2673-5. PubMed ID: 21846674
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.